FDA and CE validation RevitalVision holds FDA-cleared status for amblyopia treatment in children older than 9 and adults, with additional CPT code approvals, and CE-marking broad indication. This affords credibility for talking points with clinics and payers, supporting premium pricing and faster adoption discussions.

Clinical efficacy Clinical data show measurable vision improvements, including 2.5 lines on the visual acuity chart and a 100% average increase in contrast sensitivity across product categories. Use these metrics to craft ROI-focused conversations with eye care specialists and clinics about patient outcomes and potential throughput gains.

Revenue potential Current revenue range indicates a scalable SaaS-based model with B2B opportunities across eye care specialists and surgery clinics seeking new revenue streams and reduced post-surgery visits. Target medium-sized clinics and ophthalmology networks aiming to differentiate services.

Market readiness Recent press highlights U.S. market entry and awards for non-invasive brain-tech algorithms, signaling strong market validation and readiness for expansion into optometry groups, vision centers, and corporate healthcare networks seeking innovative vision solutions.

Expansion and partnerships Existing validation through trial participants and commercial customers suggests potential partnerships with clinics, hospital systems, and vision networks, as well as opportunities to pilot programs in regions with high amblyopia prevalence and unmet vision treatment needs.